Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2004

01-04-2004

Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma

Authors: Takuji Okusaka, Shuichi Okada, Toshio Nakanishi, Shigetoshi Fujiyama, Yasuhiko Kubo

Published in: Investigational New Drugs | Issue 2/2004

Login to get access
Metadata
Title
Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma
Authors
Takuji Okusaka
Shuichi Okada
Toshio Nakanishi
Shigetoshi Fujiyama
Yasuhiko Kubo
Publication date
01-04-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 2/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000011793.72775.d1

Other articles of this Issue 2/2004

Investigational New Drugs 2/2004 Go to the issue

OriginalPaper

Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

OriginalPaper

Resveratrol Antagonizes EGFR-Dependent Erk1/2 Activation in Human Androgen-Independent Prostate Cancer Cells with Associated Isozyme-Selective PKCα Inhibition

OriginalPaper

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

OriginalPaper

The New Isothiocyanate 4-(Methylthio)Butylisothiocyanate Selectively Affects Cell-Cycle Progression and Apoptosis Induction of Human Leukemia Cells

OriginalPaper

Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer

OriginalPaper

A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits